On October 22, 2026, enterprise software provider Genedata announced the integration of NVIDIA BioNeMo open models into its AI-enabled biopharmaceutical discovery workflows. The update includes the newly introduced RFD4-Proteina binder design model.
AI Discovery Workflows
Genedata announced the addition of the RFD4-Proteina binder design model into its AI-enabled discovery workflows on October 22, 2026. The integration follows the model's introduction at NVIDIA GTC Berlin, making Genedata an early ecosystem partner to offer the model within production discovery workflows.
According to Genedata, the discovery process begins when scientists define target characteristics using the platform's AI co-scientist. NVIDIA's open protein design models then generate and evaluate candidate binders directly within Genedata.
Closed-Loop Discovery
As candidates move into laboratory testing, experimental results are captured and linked back to original designs to help researchers refine subsequent rounds. Genedata stated that the setup connects molecular design, experimental execution, and scientific data into a continuous learning cycle.
Within Danaher's autonomous laboratory initiative, these connected capabilities aim to link AI, automation, and scientific data to advance research while keeping scientists in control.
Key facts and where they come from
- Genedata added the RFD4-Proteina binder design model to its AI-enabled workflows.
the addition of the new RFD4-Proteina binder design model into Genedata's AI-enabled discovery workflows
- The integration follows the model's introduction at NVIDIA GTC Berlin.
following the model's introduction at NVIDIA GTC Berlin.
Read the original from Company press releases (PR Newswire) →